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Abstract
Background: It is well known that the prognosis of castration-resistant prostate cancer
(CRPC) is poor, and several immunotherapeutic strategies have been applied to the clinical
trials. Research on immunotherapy has been of special interest for the treatment of CRPC for
years.
Objective: To evaluate the safety of personalized peptide vaccine (PPV) immunotherapy and
its clinical outcomes.
Design, setting, and participants: A phase 2 randomized controlled trial of PPV immunother-
apy with low-dose dexamethasone versus dexamethasone alone for chemotherapy-naive
CRPC began in 2008. Eligible patients (prostate-speciﬁc antigen [PSA]<10 ng/ml)were human
leukocyte antigen (HLA) A02, A24, or A03 superfamily positive and had asymptomatic or
minimally symptomatic CRPC. Patients were allocated (1:1) to PPV plus dexamethasone
(1 mg/d) or to dexamethasone (1 mg/d) alone. A maximum of four HLA-matched peptides
(each 3 mg) was selected based on the preexisting immunoglobulin G responses against the
24 warehouse peptides and administered every 2 wk.
Outcome measurements and statistical analysis: PSA, progression-free survival (PFS), time to
initiation of chemotherapy, and overall survival (OS) were analyzed using the Kaplan-Meier
method, a log-rank test, and proportional hazard analysis.
Results and limitations: Overall, 37 patients received peptide vaccinations and 35 received
dexamethasone alone. The primary end point was PSA PFS, which was signiﬁcantly longer in
the vaccination group than in the dexamethasone group (22.0 vs 7.0 mo; p = 0.0076). Median
OS was also signiﬁcantly longer in the vaccination group (73.9 vs 34.9 mo; p = 0.00084). The
relatively small number of patients enrolled is the major limitation of the study.
Conclusions: PPV immunotherapy was well tolerated and associated with longer PSA PFS and
OS in men with chemotherapy-naive CRPC. A larger phase 3 study is needed to conﬁrm our
ﬁndings.
Patient summary: We compared clinical outcomes of the treatment with personalized
peptide vaccine plus dexamethasone versus dexamethasone alone. Our data provide promis-
ing evidence of clinical beneﬁt for peptide vaccines.
Trial registration: UMIN-CTR: 000000959.
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Since Charles Huggins reported that prostate cancer (PCa)
would regress in response to androgen ablation in 1941,
primary androgen deprivation still remains the initial
therapy for metastatic PCa. However, the disease becomes
lethal when progression occurs despite the low levels of
testosterone, which is then referred to as castration-
resistant prostate cancer (CRPC). During the past few years,
the treatment options for metastatic CRPC (mCRPC) have
changed remarkably. During that time, several new agents
have become available to treat men with mCRPC including
abiraterone [1], enzalutamide [2], cabazitaxel [3], and
sipuleucel-T [4]. Despite these advances, median survival
for patients with postchemotherapy mCRPC is about 2 yr
[1]. In phase 3 trials of abiraterone and enzalutamide in the
chemotherapy-naive mCRPC setting, the median overall
survival (OS) in the treatment arm was 34 and 32 mo,
respectively [5,6]. Immunotherapy with sipuleucel-T is the
first therapeutic cancer vaccine demonstrated to improve
outcomes in an advanced malignancy and provides
possibilities for further investigation of immunotherapy
for mCRPC.
Under these circumstances,multiple immune approaches
beyond sipuleucel-T are currently under development that
include antigen-directed immunotherapies as well as
monoclonal antibodies against immune checkpoints. Com-
bination therapies of immunotherapy and conventional
therapies are also being evaluated.
Personalized peptide vaccination (PPV) is an immuno-
therapy that uses multiple cancer peptides based on the
preexisting host immunity. Tumor-associated antigen
peptides derived from the tumor cells are recognized
by antigen presenting cells that in turn present these to
CD4+ and CD8+ T cells by way of major histocompatibility
complexes class I and II molecules, respectively. This
interaction leads to the induction and proliferation of
cytotoxic T lymphocyte (CTL) precursors, which will then
establish an antigen-specific population aimed at
destroying cancer cells. We previously reported that
PPV was safe and improved clinical outcomes with
immune responses in phase 1 and 2 clinical trials in
patients with CRPC [7–9]. In addition, low-dose dexa-
methasone is known as one of the treatment options by
itself or with PPV for CRPC patients [10–12]. The longer
acting dexamethasone could elicit more effective sup-
pression of adrenocorticotropic hormone, and as a result,
it shows higher antitumor activity. Dexamethasone is
reported to have an antiangiogenic effect in vivo and also
has the effect of reducing expression of androgen
receptors [13,14].
At the time the study was conducted, low-dose
dexamethasone was considered the standard of care and
hence had the rationale to be provided as monotherapy in
the comparator arm. In this article, clinical outcomes of PPV
immunotherapy in combination with low-dose dexameth-
asone are compared with dexamethasone alone in a
randomized controlled study.2. Patients and methods
2.1. Patient eligibility
The eligible criteria included that patients had positive regional lymph
nodes and/or distantmetastases at the diagnosis of PCa. Patients<80 yr of
age with progressive CRPC regardless of androgen deprivation, life
expectancy >3 mo, Eastern Cooperative Oncology Group (ECOG)
performance status of 0 or 1, prostate-speciﬁc antigen (PSA) <10 ng/ml,
and a castrate testosterone level (<50 ng/dl), and human leukocyte
antigen (HLA) A2, A24, or A03 positive and pathologically conﬁrmed
adenocarcinoma of the prostate were eligible. PSA progression was
deﬁned as two consecutive 25% increases frombaseline PSA levels at least
2 wk apart as described by Bubley et al [15]. Antiandrogen agent was
discontinued for 4 wk before enrollment for patients receiving ﬂutamide
and 6 wk for those receiving bicalutamide. Patients without orchiectomy
continued on androgen deprivation therapy with a luteinizing hormone-
releasing hormone agonist throughout the study. Patients needed to have
positive immunoglobulinG (IgG) responses to at least one of the candidate
cancer peptides. Other eligibility criteria included adequate hematologic,
hepatic, and renal function, and negative serologic tests for hepatitis B,
hepatitis C, andhuman immunodeﬁciency virus. Patientswith evidence of
serious illness, active secondary malignancy within the last 5 yr prior to
enrollment, immunosuppression, or autoimmune disease were excluded
from the study. This studywas approved by both the Kinki University and
Jikei University institutional review boards (IRBs), and all patients signed
IRB-approved informed consent forms before beginning screening
procedures. This study was registered at the UMIN clinical trial registry
(UMIN-CTR, #000000959), on January 1, 2008.
2.2. Peptide preparation
A total of 24 peptides restrictedwith HLA-A02, A24, or A03were prepared
under conditions of Good Manufacturing Practice by the PolyPeptide
Laboratories (San Diego, CA, USA) or the American Peptide Company
(Vista, CA, USA) (Table 1). Previous studies have indicated that all peptides
can induce HLA-A02, A24, or A03-restricted and tumor-speciﬁc CTL
activity in peripheral bloodmononuclear cells (PBMCs) of cancer patients
[16–18]. For each patient, HLA-type speciﬁc peptides were chosen based
on the evaluation of both antipeptide IgG levels in plasma and CTL
precursors in PBMCs as described previously [16–18]. Only the reactive
peptides (a maximum of four) were used for vaccinations.
2.3. Study design and treatment protocol
This randomized controlled study involved two institutions in Japan.
Patientswere randomly assigned to one of the two arms designated as the
vaccination arm and the dexamethasone arm. A centrally administered
randomization method was used to assign patients to the arms in a 1:1
ratio. The primary end point was PSA progression-free survival (PFS). The
secondary end points were time to initiation of chemotherapy and OS.
In the vaccination arm, 3 mg peptides was injected subcutaneously
into the thigh area withMontanide ISA51VG (Seppic, Paris, France) every
2 wk (a maximum of four peptides per vaccination). The peptide
vaccination was continued at 2-wk intervals in six vaccination cycles,
until death, intolerance,marked disease progression,major violations, or
patients’ withdrawal of consent. Also, 1 mg dexamethasone per day was
administered throughout the treatment. In the dexamethasone arm,
only 1 mg dexamethasone per day was initially administered, and when
the patient was evaluated with progressive disease (PD) by PSA testing,
those in this arm were allowed to cross over to the vaccination arm, and
peptide vaccination was added in the samemanner as in the vaccination
arm (Supplementary Fig. 1). When PSA progression was found even after
vaccination, patients in both arms were offered poststudy treatments
Table 1 – Peptide candidates for personalized peptide vaccine immunotherapy
Candidate peptide
HLA-A2 HLA-A24 HLA-A3
Origin protein Amino acid sequence Origin protein Amino acid sequence Origin protein Amino acid sequence
SART3 LLQAEAPRL SART2 DYSARWNEI SART3 WLEYYNLER
Cyclophilin B KLKHYGPGWV SART3 VYDYNCHVDL SART3 QIRPIFSNR
p56 lck KLVERLGAA p56 lck HYTNASDGL p56 lck ILEQSGWWK
p56 lck DVWSFGILL p56 lck DYLRSVLEDF p56 lck VIQNLERGYR
ppMAPkkk DLLSHAFFA MRP3 RYLTQETNKV PAP GIHKQKEKSR
WHSC2 ASLDSDPWV PAP LYCESVHNF PSA GAAPLILSR
UBE2V RLQEWCSVI PSA HYRKWIKDTI IEX-1 APAGRPSASR
HNRPL NVLHFFNAPL EGF-R DYVREHKDNI b-tublin5 KIREEYPDR
HLA = human leukocyte antigen.
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and toxicity evaluations were conducted every 2 wk.
2.4. Statistical analyses
All patients who received more than six vaccinations were considered
evaluable for response. To detect the difference of PSA PFS, use of the log-
rank test of equal proportions required 36 patients per arm with a two-
sidedaof0.05and80%power. Therefore,weplanned to recruit40patients
per arm to ensure 36 evaluable patients. Data were analyzed at the end of
March 2015 using commercially available computer software. Survival
wascalculated fromthedateofﬁrst administrationto thedateofanycause
of death. Patients lost to follow-upwere censored at the last knowndate of
survival. TheKaplan-Meiermethodwasused toestimateactuarial survival
curves, and the groups were compared using a log-rank test and
proportional hazard analysis (for estimation of hazard ratio [HR]).
Differences were considered statistically signiﬁcant when p < 0.05.
3. Results
3.1. Patient characteristics
Between April 2008 and October 2013, 83 patients were
assessed for eligibility at the two study centers. Ten[(Fig._1)TD$FIG]Assessed for eligibility
(n = 83)
Randomly allocated
(n = 73)
Allocated to vaccinaon  (n = 37)
Received vaccinaon      (n = 37)
Did not receive vaccinaon (n = 0)
Lost to follow-up                  (n = 0)
Disconnued vaccinaon (n = 0)
Analyzed             (n = 37)
Excluded from analysis (n=0)
Fig. 1 – Disposition of patipatients did not meet the inclusion criteria. A total of
37 patients were randomly assigned to the peptide
vaccination arm, and 36 patients were randomly assigned
to the dexamethasone arm (Fig. 1). The 73 patients (37 in
the vaccination arm and 36 in the dexamethasone arm)
comprised the primary analysis set. Table 2 shows the
main baseline patient characteristics and reveals that
the arms were favorably balanced allowing for 1:1
randomization. Most patients had a Gleason score of
7–10 (89.2% in the vaccination arm and 88.6% in the
dexamethasone arm). The median PSA levels at baseline
were 4.39 ng/ml (vaccination arm) and 5.32 ng/ml
(dexamethasone arm), respectively. No patients in both
arms discontinued the treatment protocol for reasons
other than disease progression such as intolerance or
protocol violation.
3.2. Short-term cancer control and overall survival
A decline from baseline >50% of PSA levels at 12 wk was
found in 59.6% patients in the vaccination arm and in 54.3%
in the dexamethasone arm, respectively, which revealed no
statistical difference (Fig. 2). Five patients in the vaccinationExcluded                                        (n = 10)
Not meeng inclusion criteria (n = 10)
Refused to parcipate               (n = 0)
Other reasons                              (n = 0)
Allocated to dexamethasone  (n = 36)
Received dexamethasone     (n = 35)
Did not receive dexamethasone (n = 1)
Lost to follow-up                          (n = 0)
Disconnued dexamethasone (n = 0)
Analyzed             (n = 36)
Excluded from analysis (n = 0)
ents: study flowchart.
Table 2 – Comparison of baseline patient characteristics between
the arms
Treatment arm Vaccine and Dex
n = 37
Dex alone
n = 36
Age, yr
Median (IQR) 68 (64–73) 67 (63–67)
PSA, ng/ml
Median (IQR) 4.39 (2.16–6.85) 5.32 (3.45–7.38)
Years from initial diagnosis
Median (IQR) 2.9 (1.5–4.4) 2.7 (1.2–4.1)
Gleason score
8–10 27 25
7 6 6
6 2 2
Unknown 2 2
Prostatectomy
Yes 8 9
EBRT
Yes 12 9
Site of metastasis 25 26
Bone 25 26
LN 10 13
Lung 2 2
Previous therapy
Bicalutamide 33 33
Flutamide 18 9
Chlormadinone acetate 5 2
Estramustine phosphate 5 4
LHRH analog 34 34
Dex = dexamethasone; EBRT = external-beam radiation therapy; IQR =
interquartile range; LHRH = luteinizing hormone-releasing hormone; LN =
lymph node; PSA = prostate-speciﬁc antigen.
E U RO P E AN URO LOG Y 7 0 ( 2 0 1 6 ) 3 5 – 4 138arm (13.5%) and seven patients in the dexamethasone arm
(20.0%) showed >90% decline of PSA.
Median PSA PFS was 665 d (22.0 mo) in the vaccination
arm and 210 d (7.0 mo) in the dexamethasone arm,
respectively (Fig. 3a). The HR estimated from stratified
proportional hazard analysis is 0.389 (95% confidence
interval [CI], 0.222–0.684), and the stratified log-rank
p value for PSA PFS is 0.0076. Median time to initiation of
chemotherapy was 1576 d (52.4 mo) in the vaccination arm
and 719 d (23.8 mo) in the dexamethasone arm, respec-
tively (Fig. 3b; p = 0.047). In the vaccination arm, median[(Fig._2)TD$FIG]Fig. 2 – Waterfall plots of prostate-specific antigen decline at 12 wk after adm
Dex = dexamethasone.number of vaccinations was 32 times (range: 4–107 times).
In the dexamethasone arm, all patients received peptide
vaccinations after disease progression. Median PSA level at
crossover was 5.49 ng/ml (range: 0.35–20.41), and median
number of vaccinations was 6 times (range: 3–10 times).
Median PSA PFS after crossover was 84 d (range: 28–161 d)
(Supplementary Table 1).
The estimated median OS for the vaccination arm and
dexamethasone arm was 2219 d (73.9 mo) and 1054 d
(34.9 mo), respectively. Figure 3c shows graphs of the
Kaplan-Meier estimator of the survival distributions. The
HR estimated from stratified proportional hazard analysis is
0.412 (95% CI, 0.205–0.828), and the stratified log-rank
p value for OS is 0.00084. Table 3 summarizes these results.
After progression, patients in both arms were offered
poststudy treatments including cabazitaxel (none in the
vaccination arm and 3 in the dexamethasone arm),
docetaxel (14 patients in the vaccination arm and 19
in the dexamethasone arm), abiraterone acetate (each 1 in
both arms), enzalutamide (1 in the vaccination arm and 2
in the dexamethasone arm), and estramustine phosphate
(4 patients in the vaccination arm and eight in the
dexamethasone arm) (Supplementary Table 2).
3.3. Adverse events
No patient showed any toxicities of grade 3. Moon face of
grade 1 or 2 was noted in 13 vaccination patients and
8 dexamethasone patients, respectively. Of the 37 patients
in the vaccination arm, 30 patients developed a grade 1 or
2 local skin reaction at the injection sites with induration,
redness, and itching. Two patients with a grade 1 and one
patient with a grade 2 fever were noted, but no medication
was required. Grade 1 fatigue was observed in two patients.
Grade 1 headache was noted in one patient, and two
patients complained of rash that resolved without any
medications. In this study, no case revealed any vascular
adverse events of grade 3, such as hypertension, bleeding,
and thromboembolism, and no hepatic or renal toxicities
(higher than grade 3) were found during vaccination
(Supplementary Table 3).inistration.
[(Fig._3)TD$FIG]
Fig. 3 – (a) Prostate-specific antigen (PSA) progression-free survival is
shown. The vaccination arm is shown as a red line; the dexamethasone
(Dex) arm is shown as a blue line. Median PSA progression-free survival
was 665 d in the vaccination arm and 210 d in the Dex arm. (b) Time to
initiation of chemotherapy is shown. The vaccination arm is shown as a
red line; the Dex arm is shown as a blue line. Median time to initiation
of chemotherapy was 1576 d in the vaccination arm and 719 d in the
Dex arm. (c) Overall survival is shown. The vaccination arm is shown as
a red line; the Dex arm is shown as a blue line. Median overall survival
was 2219 d in the vaccination arm and 1054 d in the Dex arm.
CI = confidence interval; Dex = dexamethasone.
Table 3 – Summary of the clinical results
Vaccination and Dex
n = 37
Dex alone
n = 36
PSA response rates (%)
>50% decline 22 (59.6) 19 (54.3)
>90% decline 5 (13.5) 7 (20.0)
PSA progression-free survival,
median, d
665 210
Median 95% Cl 277–1054 156–264
Hazard ratio (95% CI) 0.39 (0.22–0.68)
p value 0.0076
Time to chemotherapy initiation,
median, d
1576 719
Median 95% Cl 1203–1949 634–804
Hazard ratio (95% CI) 0.50 (0.25–1.003)
p value 0.047
Overall survival, median, d 2219 1054
Median 95% Cl 1546–2892 769–1340
Hazard ratio (95% CI) 0.41 (0.21–0.83)
p value 0.00084
Cancer death 10 25
CI = conﬁdence interval; Dex = dexamethasone; PSA = prostate-speciﬁc
antigen.
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This randomized controlled phase 2 studywas designed and
powered for the primary end point of PSA PFS, and it
succeeded in finding a statistical significance between
the two treatment arms. A strong association betweentreatment arm andOSwas revealed. PPV immunotherapy in
combination with low-dose dexamethasone for patients
with chemotherapy-naive CRPC significantly prolonged OS.
This study strongly suggests that PPV immunotherapy may
have an OS benefit. Thus it may offer a new complementary
approach to treating CRPC. One of the reasons for these
clinical outcomes may be due to the study setting. In this
study, patients with an ECOG performance status of 0 or
1 and PSA <10 ng/ml were enrolled. This suggests that
patients with early-stage CRPCmay receivemore preferable
clinical benefits regarding PSA PFS, OS, and also time to
initiation of chemotherapy.
The results of this study have demonstrated parallels
regarding clinical approaches of other immunotherapies for
mCRPC. Treatment of metastatic PCa patients with a good
prognosis with dendritic cell vaccine therapy (sipuleucel-T)
provided an improved median OS of 4.5 mo (25.9 mo for
sipuleucel-T vs 21.4mo for controls) andOS benefit (3-yr OS
of 33% vs 11%), yet it revealed only a trend toward delayed
short-term disease progression [19].
A larger phase 3 study with >500 patients confirmed
these results [4]. In addition to sipuleucel-T immunothera-
py, viral-based immunotherapy has also been reported.
PSA-TRICOM (PROSTVAC; Bavarian Nordic, Copenhagen,
Denmark) showed promising efficacy and tolerability in a
clinical trial [20,21]. PROSTVAC is a vector-based therapeu-
tic cancer vaccine composed of a series of poxviral vectors
(vaccinia during the initial priming vaccine and fowlpox for
all boosts) engineered to express PSA and a triad of human
T-cell costimulatory molecules (B7.1, ICAM-1, and LFA-3).
Although there was no improvement in PFS, the primary
end point of the study, and PSA responses were infrequent,
the vaccine improved OS when compared with placebo
(25.1 vs 16.6 mo; p = 0.006). Other immunotherapies for
mCRPC are found in the literature [22–24].
These immunotherapy trials in PCa may represent an
emerging theme of prolonged OS, without a remarkable
E U RO P E AN URO LOG Y 7 0 ( 2 0 1 6 ) 3 5 – 4 140signal of tumor shrinkage or short-term cancer control. In
the present study, the initial decline of PSA was almost
identical in both the vaccination and nonvaccination group.
This response may be due to the effect of low-dose
dexamethasone. Venkitaraman et al recently reported a
phase 2 trial of dexamethasone, in which they concluded
that dexamethasone might be more active than predniso-
lone in CRPC [25].
We estimated 6 mo of median PSA PFS with dexametha-
sonemonotherapy in chemotherapy-naive CRPC patients. It
is suggested that a specific antitumor immunity induced by
peptide vaccinations resulted in the significant delay of PSA
progression compared with dexamethasone alone (7.0 vs
22.0 mo). Despite the fact that the patients in the
dexamethasone arm were allowed to cross over the
treatment, considerable longer survival was observed in
the vaccination arm (73.9 vs 34.9 mo; p = 0.00084).
Estimated median OS at the time of study commencement
was calculated at about 27 mo in both arms when using the
Halabi nomogram [26]. Although all the patients with PSA
progression in the dexamethasone arm received vaccina-
tion therapy with the same protocol after disease progres-
sion, clinical benefits were not often seen as described in the
results. However, it would seem unlikely that this
treatment protocol delayed receiving effective subsequent
therapy with other agents and had an impact on survival. In
this study, the treatment rates of abiraterone and enzalu-
tamide were low. Thus this study was done mostly before
these agents were approved in Japan.
In the treatment of cancer, immunotherapies can
produce different response patterns and have a safety
profile distinct from conventional antitumor therapies. This
is because immunotherapies elicit antitumor effects by
inducing or enhancing patients’ immune responses. These
effects can be delayed and may manifest as a gradual
reduction in tumor growth, resulting in prolonged OS,
which is not often accompanied with objective short-term
tumor responses. Cytotoxic therapies such as chemothera-
py and radiotherapy elicit their effects directly on cancer
cells and reveal rapid tumor shrinkage in responding
patients. However, studies of immunotherapy against
cancer have demonstrated that several tumor responses
characterized as PD by the standard response criteria such
as Response Evaluation Criteria in Solid Tumors may
actually be responses to treatment [27]. Before a clinical
response, growth of existing target lesions occurs resulting
in an apparent initial tumor increase and the development
of new lesions while others show shrinkage. These mixed
response patterns are characteristic of immunotherapies
compared with conventional cytotoxic chemotherapy or
radiotherapy. Therefore, it is necessary to evaluate the
efficacy of immunotherapies in individual patients by using
modified response criteria to obtain clinical benefit,
especially on OS.
In this study, detectable antibody titers to peptides were
found (data not shown). This is consistent with our previous
observations [16–18,28]. In addition to antibody response,
CTL activity was also evaluated in every patient that
demonstrated PPV immunotherapy induced adequate CTLresponses enough to attack cancer cells (data not shown).
PPV immunotherapy was well tolerated. Most adverse
events were injection site reactions, and no patient showed
any toxicities of grade 3.
5. Conclusions
PPV immunotherapy in this randomized controlled study
was associated not only with an improved PSA PFS but
also with a remarkable prolonged OS. The observed
differences in median PSA PFS, time to initiation of
chemotherapy, and survival compared with the dexa-
methasone arm suggest significant impact. It is plausible
to speculate that patients with early-stage mCRPC could
achieve maximum clinical benefits from this PPV
immunotherapy. Further randomized trials are needed
to confirm these results.
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